VISCHER advised Nemis Technologies on the deal. NEMIS Technologies AG closed a CHF 7.75m Series A financing round with the participation of both institutional and private...
You must be a Standard 1 Year member to access this content.
VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
